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Abstract: The Nexplanon® implant is a commonly used radiopaque contraceptive device that 
contains progestogen associated with an ethylene vinyl-acetate copolymer resulting in a slow 
release of the active hormonal ingredient. It is inserted into the subdermal connective tissue 
and provides contraceptive efficacy for up to 3 years. Device removal for clinical, personal or 
device “end-of-life span” reasons is straightforward. In rare cases, implant migration can occur 
locally within centimeters of the insertion site. Distant device embolization is extremely rare 
and can result in complications including chest pain, dyspnoea, pneumothorax and thrombosis 
or prevent conception until the active ingredient is depleted. We present one such case, where a 
Nexplanon® implant embolized into the pulmonary artery of a young female patient. We describe 
the initial “missed” diagnosis of embolized device on a chest radiograph and subsequent suc-
cessful percutaneous removal once distant embolization was diagnosed.
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Introduction
The Nexplanon® implant is a commonly used radiopaque, nonbiodegradable contra-
ceptive device that contains progestogen (etonogestrel). It is normally inserted into 
the subdermal connective tissue of the nondominant upper arm approximately 10 cm 
above the medial epicondyle of the humerus. During insertion, care should be taken 
to avoid the sulcus between the biceps and triceps as the basilic vein and its branches 
lie within this region. 
Removal of the device for clinical, personal or device “end-of-life span” reasons 
is usually a simple procedure. Rarely, in 1% of cases, device removal may be com-
plicated by hematoma, broken implant or fibrous adhesions. If an implant is unable 
to be palpated at the insertion site, then it should be located as soon as possible and 
removed. Xray or ultrasound of the arm may aid localization by identification of a 
radiopaque or hyperechoic line, respectively. 
Rarely, implant migration can occur, but this is usually within a few centimeters 
of the insertion site.1,2 Distant device embolization is extremely rare and can result in 
complications including chest pain, pneumothorax, pleural irritation, vascular throm-
bosis and vascular perforation, or prevent normal conception until the active ingredient 
is depleted.3,4 There have been previous rare reports of distant device embolization 
removed by percutaneous or surgical techniques. 
Correspondence: Mohammed Majid 
Akhtar
Cardiology Registrar, c/o Cardiac 
Secretaries, Barts Heart Centre, 
St Bartholomew’s Hospital, West 
Smithfield, London EC1A 7BE, UK 
Tel +44 207 3777000
Email majid.akhtar@ucl.ac.uk
Journal name: Open Access Journal of Contraception
Article Designation: CASE REPORT
Year: 2018
Volume: 9
Running head verso: Akhtar et al


































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1






We present the case of a 31-year-old Caucasian female with a 
body mass index (BMI) of 22.6 that had a subdermal contra-
ceptive implant (Nexplanon®; Merck & Co., Inc., Whitehouse 
Station, NJ, USA) inserted into the medial aspect of the upper 
arm in 2015 for contraceptive action. There were no reported 
complications at the time of device insertion.
She presented a year later for elective device removal as 
she planned on starting a family. The implant was not palpable 
in the upper arm and unable to be localized by ultrasound or 
X-ray of the arm (Figure 1A). Etonogestrel levels were raised 
at 176 pmol/mL suggesting active implant in situ. 
The patient also reported several weeks’ history of occa-
sional nonproductive cough. She did not suffer from any 
chest pain or dyspnoea. Chest X-ray (CXR) was undertaken 
and was reported normal by local radiologists (Figure 1B). 
Given the strong clinical suspicion of embolized device, 
an unused Nexplanon® implant was shown to the reporting 
radiologists to facilitate an appreciation of the nature and 
physical characteristics of the foreign body being looked for. 
On retrospective re-review of the imaging, the radiologists 
subsequently identified the device implant on the anteroposte-
rior and lateral views of the CXR. Chest CT was undertaken 
and revealed the presence of the contraceptive implant in a 
sub-branch of the right lower lobe pulmonary artery. 
The patient was referred onward to the interventional 
cardiologists for an attempt at percutaneous extraction of the 
implant. Implications of leaving the device in situ include 
Figure 1 (A) AP radiograph (X-ray) of the left upper arm (humerus and cubital fossa) with no evidence of visible radiopaque subcutaneous contraceptive implant. (B) AP 
radiograph (X-ray) of the chest. This was initially reported as normal, but closer assessment of the right mid-zone shows the radiopaque contraceptive implant which was 
initially incorrectly interpreted as a prominent bronchovascular marking given its relatively short, linear outline (black arrow). On subsequent appreciation by the radiologists 
of the short, tubular shape of the Nexplanon® implant, the foreign body was immediately identified. (C) Judkins right (JR4) catheter positioned in the right pulmonary artery 
with the contraceptive implant visualized on fluoroscopy (black arrow). (D) Selective pulmonary angiography confirms the intravascular placement of the foreign body (black 
arrow) in a branch of the right lower lobe pulmonary artery. (E, F) AP and lateral fluoroscopy views demonstrating the utilization of a gooseneck snare to extract the foreign 
body from the pulmonary artery (black arrows). A straight-ended Terumo (Terumo Corporation, Tokyo, Japan) guidewire was utilized for support. (G, H) Explanted device 
attached to a Judkins diagnostic (JR4) catheter and the device adjacent to a 5 mL syringe to demonstrate size.
Abbreviation: AP, anteroposterior,
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Nexplanon® embolization to the pulmonary artery
infection, potential pulmonary arterial thrombus formation, 
irritant cough and reduced fertility until the active hormone 
ingredient is depleted.
The patient was keen on device extraction in view of a 
persistent cough as well as her plans for starting a family. 
As such, she was electively admitted as a day-case proce-
dure for attempt at device extraction. Routine bloods and 
electrocardiogram were unremarkable. The procedure was 
undertaken in the cardiac catheter laboratory under local 
anesthesia from the right femoral vein using biplane angi-
ography ( Figure 1C and D). A coaxial approach was used 
to introduce a series of catheters into the right pulmonary 
artery which facilitated the capture of the device using a 
gooseneck snare allowing subsequent extraction of the intact 
device (Figure 1E–H). The procedure was uneventful and 
the patient discharged later in the day. She successfully 
became pregnant 1 month later and went on to have an 
uncomplicated normal delivery.
Discussion
Implantable contraceptive devices are commonly used world-
wide for contraceptive efficacy and are preferred in certain 
patients due to improved compliance and reduced rates of 
user-related method failure.5 Over 3.3 million etonogestrel 
implants were used worldwide between 1998 and 2007.5 
Over the last decade, there has been a significant increase 
in contraception use worldwide.6 In 2015, 1% of the total 
worldwide contraceptive action was administered via con-
traceptive implants.7 
Serious adverse events from device insertion such 
as intravascular placement are extremely rare. There are 
reported to be 1.3 cases of intravascular embolized Nexpl-
anon® implants per million units sold worldwide.8 Device 
embolization should be considered if the device is not pal-
pable at the insertion site or not visualized by radiological 
assessment. To facilitate X-ray localization of the implant, 
the previous single-rod contraceptive implant (Implanon®; 
Merck & Co., Inc.) was modified by the addition of barium 
sulfate to the rod core to make it radiopaque as there were 
occasional reports of the Implanon® implant being unable to 
be located.9 This, together with the use of a new applicator 
for insertion, were designed to reduce the incidence of deep 
subcutaneous insertion.10 
There are a few reported cases of contraceptive implant 
embolization to the axillary region, some of which required 
extraction via a surgical incision.7, 11–13 There have also been 
a few reported previous cases of intravascular pulmonary 
migration of subdermal contraceptive implants.2–4,7,14–20 The 
exact mechanism by which the implant may embolize is 
unclear. However, potential mechanisms include the inad-
vertent placement of the device into the venous system or 
the placement into deeper subcutaneous tissue, which may 
predispose to migratory forces on the implant if adjacent to 
a joint. It should be noted that in this reported case, device 
insertion preceded recommendations from the manufacturer 
to avoid the biceps–triceps sulcus. The manufacturer now 
recommends insertion 8–10 cm above the medial epicondyle 
of the humerus and to avoid the sulcus. 
Patients may remain asymptomatic despite distant embo-
lization of the contraceptive implant and diagnosis might 
sometimes be made during routine clinical assessment or 
when the device is due to be removed for various other 
 reasons.7,11 Some patients, however, can develop untoward 
side effects such as chest pain or cough.3,9,15 Pulmonary 
migration has also been associated with pneumothorax.18 
Percutaneous removal of an embolized contraceptive 
implant from the pulmonary artery, using a loop snare, 
has been described previously.3,17,19,20 In cases where the 
contraceptive implant has migrated too distally to allow 
percutaneous transluminal extraction, surgical removal may 
be indicated.2 In one such case, a left basal trisegmentectomy 
under video-associated thoracoscopy was undertaken suc-
cessfully, whereas in another case at the same center, thora-
coscopic removal of the device from the pulmonary artery 
was successful without the need for pulmonary resection or 
thoracotomy.14,16 There are also reported cases of the embo-
lized device being left in situ in the pulmonary artery where 
it was felt that the risk from device extraction far outweighed 
any potential benefits or due to patient choice.4 
Concerns with late diagnosis of device embolization 
include that unless recognized early, extraction via an 
endovascular approach may be difficult or hazardous due to 
fibrous adhesion formation with an increased risk of tearing 
or damaging the adjacent pulmonary vasculature. The MHRA 
(Medicines & Healthcare products Regulatory Agency) has 
advised clinicians to undertake chest imaging if the Nexpl-
anon® implant cannot be located in the arm. 
This particular case report demonstrates a rare case of 
intravascular pulmonary migration of a contraceptive implant. 
In this case, there was a delay in diagnosis of the embolized 
implant given the lack of familiarity with the physical char-
acteristics of the device by the reporting radiologists. Where 
intravascular migration has been identified, interventional 
radiologists or interventional cardiologists may be able to 
assist in the removal of these devices using snares and allow 
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diagnosis is important to minimize the chances of adverse 
event from thrombus formation or localized adhesions and 
fibrosis, which may limit the chance of successful percuta-
neous extraction.3 Where percutaneous means of extraction 
are not feasible, there are other reported cases of minimally 
invasive surgical techniques for device removal.
In this case, multidisciplinary teamwork, with education 
of relevant health professionals, allowed subsequent rapid 
identification of the site of device embolization and suc-
cessful removal involving minimally invasive techniques. 
This highlights the importance of multidisciplinary coor-
dination and awareness of the potential complications from 
inadvertent deep contraceptive device insertion and potential 
diagnostic and therapeutic strategies to ensure a successful 
outcome for the patient.
Given the rarity of device embolization into the pulmonary 
artery, the exact mechanism by which this occurs is difficult to 
ascertain, particularly with regard to any retrospective recall 
of insertion technique or complications. The Faculty of Sexual 
and Reproductive Healthcare Clinical Effectiveness Unit now 
recommends that patients are also consented for the potential 
risk of device embolization prior to Nexplanon® insertion.21 
Only health-care professionals fully trained and competent to 
insert contraceptive devices should undertake the procedure. 
During device insertion, the skin should be tented, and the 
applicator needle should be visualized along its entire length 
in the subdermal plane to avoid accidental deep or intravas-
cular insertion. This, together with the recommended avoid-
ance of the sulcus between the biceps and the triceps, a site 
enriched with veins and tributaries is likely to be beneficial 
in avoiding inadvertent placement. After device insertion, 
both the health-care professional and the patient should be 
able to palpate the device, and the patient should inform her 
responsible health-care clinician if she can no longer palpate 
the device afterward. 
Pulmonary embolization is a rare complication of the 
Nexplanon® implant. This case highlights the importance 
of early diagnosis and a multidisciplinary approach to allow 
appropriate diagnosis and treatment of this complication. 
Endovascular approaches to device extraction, by interven-
tional radiologists or interventional cardiologists, can be 
successful with minimal morbidity and may be considered 
if available locally. 
Consent
The patient provided verbal and signed written consent for 
the development of this manuscript and its submission for 
publication. Care was taken to ensure no patient identifiable 
data was included in the manuscript. Patient written consent 
was obtained for case description and image usage.
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